Polar Capital Holdings’s Indivior Pharmaceuticals INDV Stock Holding History

Polar Capital Holdings’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-285,077	Closed	-$783M	–	289
2024 Q1	$783M	Buy	+285,077	New	+$5.36M	4.11%	4
2023 Q4	–	Sell	-2,621,150	Closed	-$60.5M	–	292
2023 Q3	$60.5M	Sell	2,621,150 -428,537	-14%	-$9.77M	0.45%	64
2023 Q2	$72.6M	Buy	+3,049,687	New	+$69.9M	0.37%	70

Other funds holding INDV

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

MGP

M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Polar Capital Holdings's INDV Position: Q2 2024 in Review

Polar Capital Holdings sold out of Indivior Pharmaceuticals (INDV) in Q2 2024, closing a stake of 285,077 shares — an estimated $783M sold.

Polar Capital Holdings first reported a position in INDV in Q2 2023 and held it in 3 quarters. The position peaked at $783M in Q1 2024. 99 funds tracked by Wall St. Rank hold INDV as of Q2 2024.

Polar Capital Holdings reported no remaining Indivior Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Polar Capital Holdings sold 285,077 Indivior Pharmaceuticals shares in Q2 2024, an estimated $783M.
Polar Capital Holdings first reported a position in Indivior Pharmaceuticals in Q2 2023 and held it in 3 quarters.
Polar Capital Holdings's Indivior Pharmaceuticals position peaked at $783M in Q1 2024.
99 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2024.

Based on Polar Capital Holdings's 13F filing for Q2 2024, filed 14 Aug 2024.